Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort

Abstract

The Hopkins Lupus Cohort is supported by RO1 AR 43727 and by the Outpatient General Clinical Research Center M01-RR00052. Received 6 June 2005; accepted 23 June 2005 The Hopkins Lupus Cohort is a prospective longitudinal study of lupus activity, organ damage, and quality of life in SLE patients. It is balanced between Caucasian and African-American SLE patients. This review highlights major findings from the cohort with implications for clinical care.

Keywords

damage disease activity hydroxychloroquine SLE

Get full access to this article

View all access options for this article.

References

Petri M , Genovese M , Engle E , Hochberg M. Definition, incidence and clinical description of flare in systemic lupus erythematosus: a prospective cohort study . Arthritis Rheum 1991; 34: 937-944 .

Barr S , Zonana-Nacach A , Magder L , Petri M. Patterns of disease activity in systemic lupus erythematosus . Arthritis Rheum 1999; 42: 2682-2688 .

Petri M , Perez-Gutthann S , Longenecker JC , Hochberg MC. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status . Am J Med 1991; 91: 345-353 .

Petri M , Conroy M , Caffentzis E , Goldman D. The evolution of systemic lupus erythematosus (SLE) (abstract) . Arthritis Rheum 1993; 36(9 Suppl): S274-S274 .

Zonana-Nacach A , Barr SG , Magder LS , Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids . Arthritis Rheum 2000; 43: 1801-1808 .

Petri M , Lakatta C , Magder L , Goldman DW. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis . Am J Med 1994; 96: 254-259 .

Petri M , Rheinschmidt M , Whiting-O’Keefe Q , Hellmann D , Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody . Ann Intern Med 1987; 106: 524-531 .

Derksen RHWM , Hasselaar P , Blokzijl L , Gmelig Meyling FHJ , de Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients . Ann Rheum Dis 1988; 47: 364-371 .

Wahl DG , Guillemin F , de Maistre E , Perret C , Lecompte T , Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis . Lupus 1997; 6: 467-473 .

10.

Somers E , Magder LS , Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE . J Rheumatol 2002; 29: 2531-2536 .

11.

George J , Afek A , Gilburd B et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies . Lupus 1997; 6: 723-729 .

12.

Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort . Thromb Res 2004; 114: 593-595 .

13.

Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . N Engl J Med 1991; 324: 150-154 .

14.

Duarte M , Conroy M , Petri M. Predictors of lupus nephritis (abstract) . Arthritis Rheum 2003; 48(9 Suppl): 580-580 .

15.

Fessler BJ , Alarcon GS , McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual . Arthritis Rheum 2005; 52: 1473-1480 .

16.

Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective . Scand J Rheumatol 1996; 25: 191-193 .

17.

Edwards MH , Pierangeli S , Liu X et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice . Circulation 1997; 96: 4380-4384 .

18.

Petri M , Howard D , Repke J. Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience . Arthritis Rheum 1991; 34: 1538-1545 .

19.

Petri M , Howard D , Repke J , Goldman DW. The Hopkins Lupus Pregnancy Center: 1987-1991 update . Am J Reprod Immunol 1992; 28: 188-191 .

20.

Gladman DD , Urowitz MB , Gough J , MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus . J Rheumatol 1997; 24: 2145-2148 .

21.

Akkasilpa S , Goldman D , Magder LS , Petri M. Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus . J Rheumatol 2005; 32: 48-50 .

22.

Akkasilpa S , Minor M , Goldman D , Magder LS , Petri M. Association of coping responses with fibromyalgia tender points in patients with SLE . J Rheumatol 2000; 27: 671-674 .

23.

Petri M , Buyon J , Skovron ML , Kim M. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures (abstract) . Arthritis Rheum 1997; 40(9 Suppl): S218-S218.

24.

Buyon JP , Petri MA , Kim MY et al. Estrogen/cyclic progesterone is associated with increased mild/moderate but not severe flares in systemic lupus erythematosus: the SELENA trial . Ann Intern Med 2005; 142: 953-962 .

25.

Petri M , Barr SG , Buyon J et al. RIFLE Responder Index for lupus erythematosus (abstract) . Arthritis Rheum. 2000; 43(9 Suppl): S244-S244 .

26.

Petri M , Brodsky R , Jones R , Gladstone D , Johnson L , Magder L. High-dose cyclophosphamide vs monthly (NIH) cyclophosphamide: one year results (abstract) . Arthritis Rheum 2004; 50(9 Suppl): S407-S407 .

27.

Hay EM , Bacon PA , Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . Q J Med 1993; 86: 447-458 .

28.

Liang MH , Socher SA , Larson MG , Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107-1118 .